Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting “real-world”1 setting FOSTER CITY, Calif., Dec. 04, 2023 -- Apollomics...

Related Keywords

China ,Illinois ,United States ,Kunpeng ,Guangdong ,Chicago ,Peter Vozzo ,Sean Leous ,Nasdaq ,Avistone Biotechnology Co ,European Society Of Medical Oncology Congress On ,Securities Exchange ,National Medical Products Administration ,Exchange Commission ,Apollomics Inc ,America Conference ,Lung Cancer ,Efficacy In Metex ,Without Concurrent ,Distributions Compared With Public Databases ,Avistone Biotechnology ,Medical Oncology Congress ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,